Business Briefing: Aetna and Gilead Reach Deal on Hep-C Drug
[one_fourth]
[/one_fourth][three_fourth_last]
Aetna said its agreement with Gilead followed a clinical review of other approved therapies for hepatitis C, which include AbbVie’s Viekira Pak.
Gilead’s Harvoni, its newest treatment, is taken as a single pill and has a list price of $94,500 for 12 weeks. Viekira Pak, which is administered in multiple pills daily, has a list price of $83,319 per treatment.
Express Scripts announced just days after regulators approved AbbVie’s Viekira Pak that it had negotiated a lower price for that treatment. CVS Health followed up by saying that it would back Gilead, as did Anthem.
